5/6 🧵
Why this matters: Current weight-loss drugs (GLP-1s) suppress appetite. Brown fat therapies could increase energy expenditure instead — burning calories rather than reducing intake. The SLIT3 pathway offers multiple intervention points: the enzyme, the fragments, or the receptors.